Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy

癌症治疗中靶向 VEGF 介导的肿瘤血管生成

• 批准号: 8719790
• 负责人: M. LUISA IRUELA-ARISPE
• 金额: $ 0.5万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-09 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8719790
• 关键词: Academia; Academy; Angiogenesis Inhibitors; Animal Model; Antineoplastic Agents; Area; Award; Biological Markers; Blood; Blood Vessels; Body part; Cancer Control; Cancer Etiology; Cardiovascular system; Child Care; Clinical; Clinical Data; Clinical Investigator; Clinical Sciences; Clinical Trials; Collaborations; Combined Modality Therapy; Communities; Congresses; Consensus; Data; Diagnosis; Disabled Persons; Discipline; Disease; Disease model; Drug Delivery Systems; Drug Industry; Drug Targeting; Drug resistance; Education; Educational workshop; Environment; Event; Excision; Faculty; Family; Fellowship; Female; Fostering; Future; Goals; Government; Human; Human Development; Hypertension; Immune response; Immunotherapeutic agent; Individual; Industry; International; Knowledge; Life; Malignant Neoplasms; Mediating; Medical Research; Mentors; Metastasis Induction; Minority; Minority Groups; Mission; Molecular; Monitor; Mus; National Cancer Institute; Neoplasm Metastasis; Neoplasms in Vascular Tissue; New York; New York City; Nutrient; Oncologist; Oral; Outcome; Oxygen; Participant; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Prize; Process; Proliferating; Proteins; Publications; Publishing; Research; Research Personnel; Research Project Grants; Resistance; Resistance development; Resolution; Risk; Safety; Science; Scientist; Signal Pathway; Signal Transduction; Staging; Technical Expertise; Technology; Therapeutic; Therapeutic Agents; Translational Research; Translations; Travel; Tumor Angiogenesis; Underrepresented Minority; United States Food and Drug Administration; Validation; Vascular Endothelial Growth Factors; Woman; abstracting; angiogenesis; antiangiogenesis therapy; anticancer research; cancer therapy; career; data exchange; disability; discount; drug development; immunoregulation; improved; innovation; knowledge translation; lectures; meetings; mouse model; novel; posters; pre-clinical; prevent; public health relevance; repository; response; symposium; tool; treatment strategy; tumor; wasting

DESCRIPTION (provided by applicant): Anti-angiogenic approaches in cancer therapy show great potential in preclinical mouse models, yet to date this potential has not been fully realized in human cancer therapy. This 2-day conference titled, "Targeting VEGF- mediated Tumor Angiogenesis in Cancer Therapy," will be presented by the New York Academy of Sciences on June 19-20, 2014, in New York City. The conference will explore our understanding of the mechanisms impacting the efficacy of existing anti-angiogenic cancer therapeutics, including discussions on biomarkers undergoing validation that may predict resistance and overall clinical outcome, with the goals of improving current treatments and developing new anti-angiogenic strategies for cancer. It is anticipated that this event will convene 250 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; oncologists; pharmaceutical strategists; and regulatory experts. The three central aims of this conference are to: (i) provide a neutral forum through lectures, a keynote presentation, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to angiogenesis-targeted cancer therapy, such as inherent and acquired resistance, compensatory angiogenic signaling, vascular normalization, immune modulation, tumor-type, -stage and -environment related drug responsiveness, biomarkers to predict responsiveness and resistance, drug safety, and combination therapy approaches for improved efficacy; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations/prizes, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboration among international investigators from all sectors to promote the translation of research into safer and more efficient cancer therapeutics. The conference goals align well with the mission of the National Cancer Institute (NCI) to support education in fundamental sciences and clinical disciplines relating to cancer, champion research projects in cancer control, and encourage cancer research by industry. In addition, the NCI's specific goal of collecting and disseminating information on cancer will be met through the publication of a post-conference, enduring, open-access, Section 508-compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the meeting to the global research and medical communities. This conference is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., blood vessel formation and immune response) and from varied scientific approaches (e.g., animal models and human clinical trials). A collaborative examination of this new information among all angiogenesis stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential innovative therapeutic approaches, such as ways to circumvent resistance and the development of biomarkers for identifying responsive patients.

描述（由申请人提供）：癌症治疗中的抗血管生成方法在临床前小鼠模型中显示出巨大潜力，但迄今为止这种潜力尚未完全实现 在人类癌症治疗中。纽约科学院将于 2014 年 6 月 19 日至 20 日在纽约市举办这次为期 2 天的会议，题为“癌症治疗中靶向 VEGF 介导的肿瘤血管生成”。会议将探讨我们对影响现有抗血管生成癌症疗法疗效的机制的理解，包括讨论正在验证的可预测耐药性和总体临床结果的生物标志物，目标是改进当前的治疗方法并开发新的癌症抗血管生成策略。预计本次活动将有 250 名与会者，包括学术界、工业界和政府的基础科学家和临床研究人员；肿瘤学家；医药策略师；和监管专家。本次会议的三个中心目标是：（i）通过讲座、主题演讲、互动辩论和网络活动提供一个中立的论坛，讨论血管生成靶向癌症治疗的当前障碍和新兴创新方法，例如固有和获得性耐药、代偿性血管生成信号、血管正常化、免疫调节、肿瘤类型、阶段和环境相关药物 反应性、预测反应性和耐药性的生物标志物、药物安全性以及提高疗效的联合治疗方法； (ii) 通过简短演讲、海报展示/奖品、旅行奖学金、职业指导活动和折扣注册，展示和鼓励早期职业、女性和代表性不足的少数族裔调查员的参与； (iii) 促进各个部门的国际研究人员之间的合作，以促进研究成果转化为更安全、更有效的癌症治疗方法。会议目标与美国国家癌症研究所 (NCI) 的使命高度契合，即支持与癌症相关的基础科学和临床学科教育、支持癌症控制研究项目并鼓励行业进行癌症研究。此外，NCI 收集和传播癌症信息的具体目标将通过在《纽约科学院年鉴》中出版一份会后、持久、开放获取、符合第 508 条的会议报告来实现，该报告将向全球研究和医学界分发会议上交流的科学知识和思想。鉴于不同研究领域（例如血管形成和免疫反应）和不同科学方法（例如动物模型和人体临床试验）中出现了大量新数据，这次会议显得尤为及时。因此，所有血管生成利益相关者对这一新信息的协作检查对于指导该领域的研究具有重要价值，特别是在潜在的创新治疗方法方面，例如规避耐药性的方法和开发用于识别反应性患者的生物标志物。